Erythrocyte glutathione transferase activity: A possible early biomarker for blood toxicity in uremic diabetic patients

Annalisa Noce, Raffaele Fabrini, Mariarita Dessì, Alessio Bocedi, Silvia Santini, Valentina Rovella, Anna Pastore, Manfredi Tesauro, Sergio Bernardini, Nicola Di Daniele, Giorgio Ricci

Research output: Contribution to journalArticlepeer-review


Erythrocyte glutathione transferase (e-GST) displays increased activity in patients with renal damage and positive correlation with homocysteine (Hcy) in patients under maintenance hemodialysis. Here, we determined e-GST, Hcy, and erythrocyte catalase (e-CAT) in 328 patients affected by type 2 diabetes mellitus (T2DM), 61 diabetic non-nephropathic patients and 267 affected by diabetes and by chronic kidney disease (CKD) under conservative therapy subdivided into four stages according to K-DOQI lines. e-GST activity was significantly higher in all T2DM patients compared to the control group (7.90 ± 0.26 vs. 5.6 ± 0.4 U/gHb), and we observed an enhanced activity in all subgroups of CKD diabetic patients. No significant correlation or increase has been found for e-CAT in all patients tested. Mean Hcy in diabetic patients is higher than that in healthy subjects (33.42 ± 1.23 vs. 13.6 ± 0.8 μM), and Hcy increases in relation to the CKD stage. As expected, a significant correlation was found between e-GST and Hcy levels. These findings suggest that e-GST hyperactivity is not caused directly by diabetes but by its consequent renal damage. e-GST, as well as Hcy, may represent an early biomarker of renal failure.

Original languageEnglish
Pages (from-to)219-224
Number of pages6
JournalActa Diabetologica
Issue number2
Publication statusPublished - 2014


  • Chronic kidney disease
  • Diabetes
  • Erythrocyte catalase
  • Erythrocyte glutathione transferase
  • Homocysteine

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Erythrocyte glutathione transferase activity: A possible early biomarker for blood toxicity in uremic diabetic patients'. Together they form a unique fingerprint.

Cite this